Daphne L. Farrington

758 total citations
19 papers, 471 citations indexed

About

Daphne L. Farrington is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Daphne L. Farrington has authored 19 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Genetics. Recurrent topics in Daphne L. Farrington's work include Cancer-related Molecular Pathways (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Daphne L. Farrington is often cited by papers focused on Cancer-related Molecular Pathways (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Daphne L. Farrington collaborates with scholars based in United States, Germany and Australia. Daphne L. Farrington's co-authors include Robert J. Konrad, James S. Bourdage, Marc S. Mendonca, Jeffrey R. Infante, Howard A. Burris, Katherine M. Bell‐McGuinn, J. Leslie Redpath, David A. Boothman, George R. Simon and Michael Lahn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Immunological Methods.

In The Last Decade

Daphne L. Farrington

18 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daphne L. Farrington United States	12	293	155	133	111	71	19	471
Christian Wichmann Germany	16	301 1.0×	155 1.0×	109 0.8×	73 0.7×	50 0.7×	61	583
Gou Watanabe Japan	11	201 0.7×	306 2.0×	102 0.8×	124 1.1×	67 0.9×	25	596
Marion Chapellier France	12	153 0.5×	148 1.0×	94 0.7×	100 0.9×	43 0.6×	28	467
Rocío Vicario United States	7	172 0.6×	157 1.0×	78 0.6×	117 1.1×	36 0.5×	8	395
Bruno Fang United States	11	231 0.8×	189 1.2×	59 0.4×	64 0.6×	148 2.1×	33	458
Timothy N. Trotter United States	14	163 0.6×	240 1.5×	61 0.5×	126 1.1×	25 0.4×	22	494
Candice McCoy United States	11	286 1.0×	233 1.5×	47 0.4×	106 1.0×	171 2.4×	27	501
Viola Allaj United States	6	282 1.0×	352 2.3×	69 0.5×	163 1.5×	87 1.2×	12	619
Linda Lam United States	8	203 0.7×	131 0.8×	113 0.8×	40 0.4×	202 2.8×	23	467
Andrew Elliott United States	10	191 0.7×	260 1.7×	65 0.5×	54 0.5×	146 2.1×	99	483

Countries citing papers authored by Daphne L. Farrington

Since Specialization

Citations

This map shows the geographic impact of Daphne L. Farrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daphne L. Farrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daphne L. Farrington more than expected).

Fields of papers citing papers by Daphne L. Farrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daphne L. Farrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daphne L. Farrington. The network helps show where Daphne L. Farrington may publish in the future.

Co-authorship network of co-authors of Daphne L. Farrington

This figure shows the co-authorship network connecting the top 25 collaborators of Daphne L. Farrington. A scholar is included among the top collaborators of Daphne L. Farrington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daphne L. Farrington. Daphne L. Farrington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Patel, Manish, Gerald S. Falchook, Alexander I. Spira, et al.. (2025). First-in-human (FIH) phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 3042–3042.

Spira, Alexander I., Roisin E. O’Cearbhaill, Patricia LoRusso, et al.. (2024). A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3166–TPS3166. 2 indexed citations

Frangoul, Haydar, Christopher McKinney, Luis Piñeiro, et al.. (2024). AsCas12a Gene Editing of HBG1/2 Promoters with Edit-301 Results in Early and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia. Transplantation and Cellular Therapy. 30(2). S238–S239. 5 indexed citations

Frangoul, Haydar, Christopher McKinney, Luis Piñeiro, et al.. (2023). AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia. Blood. 142(Supplement 1). 4996–4996. 11 indexed citations

Kollmannsberger, Christian, Carolyn D. Britten, Anthony J. Olszanski, et al.. (2021). A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer. Investigational New Drugs. 39(6). 1613–1623. 17 indexed citations

Vergote, Ignace, Florian Heitz, Paul Buderath, et al.. (2019). A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology. 156(1). 23–31. 43 indexed citations

Bendell, Johanna C., Helge Bischoff, Jimmy J. Hwang, et al.. (2019). A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational New Drugs. 38(4). 1145–1155. 20 indexed citations

Vergote, Ignace, Florian Heitz, Paul Buderath, et al.. (2019). A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology. 37(15_suppl). 5537–5537. 3 indexed citations

Infante, Jeffrey R., Amita Patnaik, Claire F. Verschraegen, et al.. (2017). Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 79(2). 315–326. 29 indexed citations

10.

Goldman, Jonathan W., Lee S. Rosen, Anthony W. Tolcher, et al.. (2017). Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Investigational New Drugs. 36(4). 629–637. 13 indexed citations

11.

Gray, Jhanelle E., Jeffrey R. Infante, Les Brail, et al.. (2015). A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Investigational New Drugs. 33(6). 1187–1196. 59 indexed citations

12.

Shih, Kuang‐Chung, J. R. Infante, Kyriakos P. Papadopoulos, et al.. (2011). A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642).. Journal of Clinical Oncology. 29(15_suppl). 2600–2600. 3 indexed citations

13.

Brail, Leslie H., George R. Simon, Suzanne F. Jones, et al.. (2011). A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin.. Journal of Clinical Oncology. 29(15_suppl). 3030–3030. 4 indexed citations

14.

Baselga, José, Mace L. Rothenberg, Josep Tabernero, et al.. (2008). TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers. 13(2). 217–236. 52 indexed citations

15.

Farrington, Daphne L., Jonathan M. Yingling, Lei Yan, et al.. (2007). Development and validation of a phosphorylated SMADex vivostimulation assay. Biomarkers. 12(3). 313–330. 17 indexed citations

16.

Bourdage, James S., et al.. (2007). An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. Journal of Immunological Methods. 327(1-2). 10–17. 111 indexed citations

17.

Mendonca, Marc S., Daphne L. Farrington, Yan Qin, et al.. (2004). Homozygous deletions within the 11q13 cervical cancer tumor‐suppressor locus in radiation‐induced, neoplastically transformed human hybrid cells. Genes Chromosomes and Cancer. 39(4). 277–287. 14 indexed citations

18.

Mendonca, Marc S., et al.. (1999). Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells.. PubMed. 59(16). 3972–9. 42 indexed citations

19.

Mendonca, Marc S., Ken Howard, Clare L. Fasching, et al.. (1998). Loss of Suppressor Loci on Chromosomes 11 and 14 May Be Required for Radiation-Induced Neoplastic Transformation of HeLa × Skin Fibroblast Human Cell Hybrids. Radiation Research. 149(3). 246–246. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact